Thrombologic ApS

Thrombologic is a small seed-capital biotech company based in Denmark that’s developing new discoveries from Rigshospitalet (Copenhagen University Hospital) and leading frontier investigators to develop life-saving therapies for critically ill patients suffering from sepsis and multiple organ failure.
With the backing of seed investment companies Novo Seeds and CATScience, Thrombologic’s goal is to take its unique and proprietary approach from theoretical idea to experimental data – and produce enough data to support
a clinical proof of concept study where both the effect and the safety of the treatment can be thoroughly tested.